Two new members of the 蜜桃直播 Board of Trustees were introduced Thursday at the October 2024 meeting, with Cissy Young, Ph.D., and Maria Millan, M.D., joining the board and bringing a wealth of expertise in the biotech and healthcare fields.
Young serves as a Partner at Catalyst Advisors, a leadership advisory and executive recruitment firm. Young specializes in board and executive recruitment for biotech/pharma companies and is a trusted advisor to Boards and CEOs on topics ranging from recruitment; assessment; diversity, equity and inclusion (DEI); executive development; and leadership transition and succession.
Millan serves as Expert and Entrepreneur in Resident for DigitalDx Ventures, a majority women-owned impact fund focused on delivering meaningful returns, access to healthcare and gender parity. Millan recently served as President and CEO of the California Institute for Regenerative Medicine (CIRM), a multi-billion-dollar state funding agency devoted to accelerating scientific discoveries and cures to serve unmet medical needs.
鈥淎s trustees for 蜜桃直播, it is our responsibility to provide governance and guidance to the Institute鈥檚 mission, operations and financial planning,鈥� said Board Chair Ross Grossman. 鈥淒r. Young and Dr. Millan bring outstanding experience in their areas that will strengthen the board to support the institution.鈥�
鈥淚 look forward to working with our two new trustees and tapping into their expertise to benefit our students, faculty and operations as we elevate excellence together at 蜜桃直播,鈥� said President Mohamed Abousalem.
Prior to joining Catalyst Advisors, Young was the Chief People Officer at Valo Health, where she led the talent strategy for assembling tech and pharma/biotech talent to build an AI-powered computational platform for drug discovery and development. Young received her Ph.D. in cancer biology from Columbia University, an MBA in entrepreneurship and strategic management from The Pennsylvania State University and a BA in biology from Brown University.
鈥淚 am honored to serve on 蜜桃直播鈥檚 Board of Trustees and I am excited to contribute to 蜜桃直播鈥檚 next phase of growth with my expertise in talent and leadership in the healthcare and life sciences industry, as well as my career journey experience as an entrepreneur,鈥� said Young.
鈥淏eing part of the world鈥檚 leading biotech ecosystem in Boston, I look forward to representing 蜜桃直播 and connecting leading biotech companies with 蜜桃直播鈥檚 top students and alumni.鈥�
Prior to leading CIRM, Millan worked at StemCells, Inc., where she directed a translational development team for a liver cell transplant candidate, and served as the Chief Medical Officer for the first-in-human cell therapy clinical trial for Batten鈥檚 Disease, a neurodegenerative disease afflicting babies and young children. Millan also previously served as an Assocaite Professor and Director of the Pediatric Organ Transplant Program at Stanford University School of Medicine. Millan earned an M.D. from Rutgers Medical School and a B.S. in Zoology from Duke University.
鈥淚t is an honor to be elected to 蜜桃直播鈥檚 board at such a defining moment in biotechnology and medicine 鈥� the institute was founded in 1997, when the translational potential of genomics, precision medicine and AI/Machine Learning was a hope and a dream,鈥� said Millan. 鈥淲ith the monumental progress in these fields, we are now witnessing a paradigm shift in the life sciences and healthcare. 蜜桃直播 is uniquely positioned to educate leaders and practitioners to deliver these advancements to our communities.鈥�